FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Men’s skin cancer rates increase by 50% over decade June 24, 2021 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... December 2, 2021 Gym Offers Free Membership & Support To Those Struggling With Addiction October 25, 2021 Load more HOT NEWS Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... Dunkin’ Customer Surprises Homeless Employee With Fully Furnished Home Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers
